Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Children with a History of Multisystem Inflammatory Syndrome in Children: An International Survey - 15/09/22
MIS-C researchers∗
Antoni Soriano-Arandes, MD, PhD 3, Emilie Pauline Buddingh, MD, PhD 4, Elizabeth Whittaker, MD, PhD 5, 6, Alexandre Belot, MD, PhD 7, Rolando Ulloa-Gutierrez, MD 8, Peter Olbrich, MD, PhD 9, 10, † , Filomeen Haerynck, MD, PhD 1, 2, ⁎, †
Abstract |
The optimal severe acute respiratory syndrome coronavirus 2 vaccine strategy for patients with a history of multisystem inflammatory syndrome in children (MIS-C) is unclear. We performed an international survey (32 countries) and found substantial variations in vaccine policies. Respondents did not report relapses of MIS-C or other severe inflammatory side effects after severe acute respiratory syndrome coronavirus 2 vaccination in 273 patients with a history of MIS-C.
Le texte complet de cet article est disponible en PDF.Keywords : MIS-C, SARS-CoV-2, COVID-19, vaccination, adverse events
Abbreviations : AE, MIS-C, SARS-CoV-2
Plan
L.H. was funded by the VIB Grand Challenge Programs and FWO-TBM (T004721N). F.H. is supported by Ghent University research grant (BOF-UGent), VIB Grand Challenges Programs, and the Jeffrey Modell Foundation. A.S.-A. is supported by the Departments of Health and Education of the Government of Catalonia (Spain) for the coronavirus disease 2019 Sentinel School Network project. P.O. has received funding by the Instituto de Salud Carlos III (Contrato Juan Rodés, JR18/00042), Madrid, Spain. The authors declare no conflicts of interest. |
Vol 248
P. 114-118 - septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.